Menopause Research
Private Second Brain wiki mined from your vaults. Enter hub password to continue.
That's not right. Try again.
🧠 VaultMiner Wiki
Menopause Research
← All Wikis
MenopauseResearch Wiki
A living synthesis mined nightly by VaultMiner. Domain: Menopause, HRT, women's healthy-aging research
Last updated: 2026-10-17
Cognitive and Brain Health
- Brain fog during menopause is linked to hormonal changes affecting the brain, not just stress or dementia, according to research from the SWAN Study and Dr. Lisa Mosconi's work. (source: 2026-05-24-GAoogzA-Wm4.md)
- Most brain supplements lack testing on women, despite claims to support brain health and memory in perimenopause and menopause. (source: 2026-05-26-FG6Zu2N_ltk.md)
- Only 3% of studies in neuroscience examine a female-only population, leaving significant gaps in understanding how estrogen and hormonal changes impact women's brain health. (source: 2026-04-28-s6GrCAl5tUI.md)
- Regular physical activity is associated with a reduced risk of dementia in both pre- and postmenopausal women, with even light activity like walking showing benefits in postmenopausal women with higher BMI. (source: lim-2026-role-of-physical-activity-in-protecting-against-dementia.md)
- Intrinsic neural connectivity within an emotion regulation network shows stage-specific patterns across the menopausal transition, with perimenopause characterized by distinct frontal interaction patterns. (source: weinmar-2026-distinct-intrinsic-neural-connectivity-of-an-emotion-regulation.md)
- Women account for nearly two-thirds of individuals with Alzheimer's disease and demonstrate important biological and clinical differences compared with men. APOE ε4 confers greater risk in women, while menopause, depression, chronic stress, adverse pregnancy outcomes, and metabolic dysfunction may further increase vulnerability. (source: just-2026-considerations-in-alzheimer-s-disease-in-women.md)
- Menopause marks an inflection point for vascular injury, neurodegeneration, and disability accumulation in neurological conditions like stroke, migraine, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Perimenopausal hormonal fluctuations (especially estrogen) may exacerbate migraines and seizures in susceptible women. HRT has heterogenous effects, with cognitive benefit in premature ovarian insufficiency but increased stroke risk in older women. (source: roeder-2026-the-neurology-of-menopause.md)
- Neural correlates of menopausal symptoms, measured by the Kupperman Index (KMI), demonstrate significant valence-specific patterns during an emotional Free Association Semantic Task (FAST) using functional near-infrared spectroscopy (fNIRS). Symptom severity correlates with activation in the right dorsolateral prefrontal cortex (DLPFC) and inferior frontal gyrus (IFG) during negative valence tasks, and with the left frontal eye fields (FEF) during positive valence tasks, suggesting potential neuromarkers for menopause. (source: chen-2026-neural-correlates-of-menopausal-symptoms-revealed-by-emotion-related.md)
- A randomized controlled trial found that aerobic exercise significantly improves executive functions in post-menopausal women compared to stretching/toning, with benefits emerging at 3 months and sustained at 6 months. This suggests aerobic exercise as a relevant strategy to promote brain health in women at higher risk for Alzheimer's disease. (source: sanz-2026-can-menopausal-status-moderate-the-effects-of-aerobic.md)
- Higher baseline serum GlycA (a systemic inflammatory marker) was associated with worse future working memory, while higher baseline complement factor 4 and increases in complement factor 3 and 4 over time appeared cognitively protective in midlife women from the SWAN Study. (source: qi-2026-inflammatory-and-immune-biomarkers-over-midlife-and-future.md)
- Age-associated estrogen decline is a systemic driver of neurodegeneration. In a mouse model of surgical menopause, estrogen deficiency exacerbated retinal ganglion cell (RGC) loss by about 60% and severely impaired functional recovery after ischemia-reperfusion injury. Combined treatment with the selective estrogen receptor modulator Raloxifene and the Fas receptor antagonist KP7-6 produced a powerful synergistic effect, limiting RGC somatic loss to 18% and restoring retinal function to near-physiological levels. This identifies endocrine aging as a modifiable driver of neuronal vulnerability and suggests a combinatorial therapeutic strategy for age-related neurodegenerative disorders. (source: rodak-2026-crosstalk-between-estrogen-signaling-and-fas-mediated-apoptosis-deter.md)
- HRT use within 5 years before or after menopause (OR 0.70, 95% CI 0.50-0.98) or for 8 to 16 years (OR 0.44, 95% CI 0.24-0.79) was associated with lower odds of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC), a cause of dementia resembling Alzheimer's disease, in older adults. This highlights the importance of HRT timing and duration for its potential neuroprotective effects. (source: kim-2026-hormone-replacement-therapy-and-its-association-with-late-nc.md)
- Blood proteomics of spontaneous menopause reveals dysregulation in inflammatory, synaptic, metabolic, and Alzheimer's disease biologic processes, tracking more strongly with hormones than with age. Validation in larger cohorts shows upregulation of inflammatory and catabolic processes and accelerated brain aging. Higher menopause proteomic scores are consistently associated with cognitive aging and dementia risk in older women. (source: wood-2026-blood-proteomics-of-menopause-map-to-brain-aging.md)
- Greater temporo-occipital gray matter volume and frontoparietal cortical thickness were observed in post-menopausal women compared to pre-menopausal women in a UK Biobank study of 4,098 women. Post-menopausal women showed larger volume in the right temporal lobe (including amygdala and hippocampus) extending to left temporal and occipital regions, and greater cortical thickness in the frontal lobe and supramarginal gyrus. No differences in cortical gyrification were found. The spatial pattern overlaps with regions affected early in Alzheimer's disease, and the findings may reflect compensatory mechanisms consistent with the biphasic model of brain structural changes in Alzheimer's disease. Further longitudinal research is needed. (source: tyrovolas-2026-greater-temporo-occipital-gray-matter-volume-and-frontoparietal-c.md)
Mental Health and Menopause
- Mind-body exercise (e.g., yoga, tai chi) is associated with lower depressive symptoms in Chinese perimenopausal women, and this association is linked to higher social support and subjective well-being. Urban residents reported lower levels of mind-body exercise, social support, and well-being and higher depressive symptoms compared with rural residents. (source: zhu-2026-the-association-between-mind-body-exercise-and-depressive-symptoms.md)
- Perceived stress is a central mediator linking negative life events to psychosocial quality of life during the menopausal transition, with resilience, self-efficacy, and social support acting as indirect protective factors through stress reduction. (source: kuck-2026-perceived-stress-as-a-mediator-between-negative-life.md)
- Shikimic acid (SA), a natural compound, exerts antidepressant-like effects via rapamycin-sensitive mTORC1-dependent mechanisms within the medial prefrontal cortex (mPFC) in mice. SA reversed ovariectomy-induced increases in immobility in the forced swim test, and this effect was completely prevented by intra-mPFC rapamycin, supporting SA as a candidate compound for novel rapid-acting antidepressants relevant to menopause-associated depression. (source: deyama-2026-rapamycin-sensitive-mtorc1-signaling-in-the-medial-prefrontal-cortex.md)
Hormone Replacement Therapy (HRT)
- The FDA removed the HRT 'Black Box' warning in 2025, a shift not widely discussed, and approved dual neurokinin receptor antagonists like elinzanetant, which reduce vasomotor symptoms by 74% without hormones. (source: 2026-05-26.md)
- The original Women's Health Initiative study on HRT safety is contested by modern specialists who argue it inappropriately tested older women on synthetic hormones. (source: 2026-05-26.md)
- There is debate over the safety of compounded hormone medications, with some doctors warning against them and others seeing them as necessary for specific formulations. HRT is central to this debate. (source: 2026-05-26.md)
- Doctors debate the appropriate limits for testosterone replacement therapy in women, with some maintaining levels above standard guidelines if the patient feels well. (source: 2026-05-26.md)
- The Women's Health Initiative study led to a 68% drop in HRT prescriptions by 2008, but the FDA reversed its warning in 2025 after recognizing flaws in the original study. (source: 2026-04-28-Ap0KrPbyVoU.md)
- Estrogen-only HRT was not associated with increased headache severity in postmenopausal women, while estrogen-progestin therapy was linked to worsening headaches, especially in those with a history of migraine. (source: crowe-2026-menopausal-hormone-therapy-migraine-history-and-headache-severity.md)
- Transdermal estradiol gel achieves serum levels (~60 pg/mL) associated with optimal cardiovascular and skeletal benefits while effectively reducing vasomotor symptoms. (source: piette-2026-optimizing-estradiol-serum-levels-for-optimal-skeletal-and.md)
- No flares were reported with HRT in women with acute hepatic porphyria, though flares occurred with combined oral contraceptives (46.6%) and progesterone-containing intrauterine devices (28.5%). Levonorgestrel-based therapies were better tolerated. (source: arandjelovic-2026-tolerability-of-hormonal-treatments-in-acute-hepatic-porphyria.md)
- HRT should be individualized according to comorbidities, formulation, and route, with preference for transdermal or low-dose regimens in high-risk populations. (source: sachdeva-2026-systematic-review-hormone-replacement-therapy-in-postmenopausal-wo.md)
- Hormone replacement (HRT) before brain death increases organ donation rates after catastrophic brain injury, with combinations like methylprednisolone and levothyroxine showing the greatest benefit. (source: nordham-2026-hormone-replacement-before-brain-death-increases-organ-donation.md)
- Initiating HRT within the first year after chemoradiation for locally advanced cervical cancer reduces metabolic, skeletal, and cerebrovascular morbidity and improves overall survival. (source: lu-2026-association-of-hormone-therapy-with-long-term-outcomes-after.md)
- Women with a history of pre-eclampsia have a reduced risk of breast cancer, and HRT use increases breast cancer risk similarly in women with or without a history of pre-eclampsia. (source: joensuu-2026-reduced-breast-cancer-risk-in-women-with-a.md)
- Combined menopausal HRT (estrogen-progestin) was associated with an increased risk of Parkinson's disease (RR 1.40; 95% CI 1.07-1.82), while estrogen-only therapy showed no significant association (RR 1.01; 95% CI 0.81-1.27). (source: macedo-2026-differential-effects-of-hormone-therapy-formulations-on-parkinson-s.md)
- Systemic HRT may be suitable for carefully chosen survivors of non-hormone-dependent gynecologic cancers (e.g., most vulvar, vaginal, cervical, and epithelial ovarian cancers), while patients with hormonally sensitive tumors should generally avoid systemic HRT. (source: da-2026-menopausal-hormone-therapy-and-comprehensive-postmenopausal-care-in.md)
- Nulliparity and later age at menopause were associated with higher ER-positivity in breast cancer (p-trend=0.021 and 0.001, respectively), with corresponding OR[ER+] (95% CI) = 1.49 (1.16-1.90) for nulliparous vs. parous. (source: adams-2026-clarifying-risk-factor-associations-with-quantitative-breast-tumor-fe.md)
- Current combined HRT (MHT) use was associated with lower grade breast cancer (p-trend<0.001), with OR [grade1] = 3.37 (2.69-4.21) for current vs. never users. (source: adams-2026-clarifying-risk-factor-associations-with-quantitative-breast-tumor-fe.md)
- Manufacturer-combined estrogen and progestogen therapy was associated with significantly lower risk of endometrial cancer (HR 0.592, 95% CI: 0.437-0.801), while tibolone use showed increased risk when used for more than four years (HR 1.518, 95% CI: 1.152-1.999). (source: yoon-2026-association-between-type-and-duration-of-menopausal-hormone.md)
- Higher baseline levels of LDL cholesterol when using CEE+MPA or lower levels of HDL cholesterol when using CEE resulted in an increased risk for CHD across all age groups. Prior treatment of hyperlipidemia demonstrated no increased risk of CHD in patients treated with CEE+MPA or CEE compared with those receiving placebo. (source: rossouw-2026-influence-of-cardiometabolic-status-on-cardiovascular-effects-of.md)
- Of 318,621 eligible women, 21.7% initiated systemic HRT within 1 year. Predictors of HT initiation included younger age (adjusted odds ratio [aOR] 2.17; 95% CI, 2.12-2.23), prior hysterectomy (aOR 1.98; 95% CI, 1.77-2.21), and local hormone use (aOR 3.25; 95% CI, 3.05-3.47). Initiation was significantly lower among women with obesity (aOR 0.78; 95% CI, 0.75-0.81), diabetes (aOR 0.69; 95% CI, 0.66-0.72), and Black racial identification (aOR 0.78; 95% CI, 0.68-0.89). (source: sriprasert-2026-initiation-and-duration-of-systemic-hormone-therapy-for.md)
- HRT was found to be independently associated with reduced medical complications following primary total shoulder arthroplasty (TSA), including lower incidence of acute kidney injury (AKI), urinary tract infection (UTI), pneumonia, and transfusion. (source: ninness-2026-hormone-replacement-therapy-and-complications-after-primary-total.md)
- Reanalysis of the Women's Health Initiative and recent studies have demonstrated the protective role of estrogen in cardiovascular disease (CVD) and bone health, particularly when initiated before the age of 60. There is an increased risk of venous thromboembolism (VTE) with oral formulations, but formulations using transdermal estradiol and micronized Progesterone do not appear to increase VTE risk. HRT may be helpful in perimenopausal and menopausal mood disorders. The timing hypothesis may be applicable to both CVD and cognition. (source: switzer-2026-management-of-menopausal-hormone-therapy.md)
- For otherwise healthy women less than 60 years old or within 10 years of menopause, HRT is a safe and effective treatment for vasomotor symptoms. Although the role of MHT is being studied for various preventive strategies, major medical societies do not yet recommend MHT for primary prevention. (source: switzer-2026-management-of-menopausal-hormone-therapy.md)
- Follow-up consultations for women on HRT should address symptom control, side effects, and bleeding patterns. The variety of formulations allows individualization, and initial difficulties are common but most women can stabilize therapy within a few months. (source: spencer-2026-troubleshooting-menopause-hormone-therapy.md)
- In November 2025, the FDA removed the boxed warning from menopausal hormone therapy, reflecting 20 years of evolving evidence since the Women's Health Initiative study. This change has important implications for nursing practice, requiring clinicians to update their understanding of the risk-benefit profile. (source: dang-2026-removal-of-boxed-warning-for-menopausal-hormone-therapy.md)
- Estradiol transdermal spray offers an efficient, flexible, and user-friendly option for menopausal symptom management. Evidence from RCT and real-world studies shows consistent and clinically meaningful improvements in vasomotor symptoms, sleep, mood, sexual health, and GSM. Severe hot flushes decreased by 70-90% with one to two sprays daily, satisfaction and ease-of-use ratings were high (80-90%), and tolerability was favorable with minimal local reactions. (source: hirschberg-2026-estradiol-transdermal-spray-for-menopausal-symptom-management-fr.md)
- A joint FIGO-WHF position paper recommends that women with cardiovascular disease risk factors or established ischemic heart disease (IHD) receive tailored counseling on systemic HRT (MHT). For those at high thromboembolic risk, transdermal estrogen with micronized progesterone or dydrogesterone is considered the safest regimen. Women with established IHD may receive low-dose transdermal estrogen for symptom relief after careful risk-benefit review, and all primary and secondary prevention measures including statins should be continued. A multidisciplinary approach between cardiologists, gynecologists, internists, and primary care providers is warranted for complex cases. (source: benedetto-2026-menopause-hormone-therapy-in-women-with-cardiovascular-risk.md)
Exercise and Physical Health
- Aerobic exercise alone does not reliably reduce hot flash frequency, and high-intensity interval training (HIIT) can worsen symptoms for women with elevated cortisol and poor sleep. (source: 2026-05-26.md)
- Researchers disagree on the safety of HIIT for menopausal women, with some advocating for its benefits and others warning it can overwhelm a depleted system. (source: 2026-05-26.md)
- Postmenopausal women cannot out-exercise visceral fat with cardio alone; resistance training and dietary changes are more effective, particularly given the role of obesity in metabolic risk. (source: 2026-05-25-tqktQoWSaWE.md)
- Women in perimenopause and menopause have different strength and cardiovascular needs than younger women, requiring tailored exercise routines. (source: 2026-05-12-7-c9tHCf7X0.md)
- Oestrogen deficiency (ovariectomized model) impairs serial sarcomerogenesis and functional recovery following immobilization in female skeletal muscle, suggesting estradiol's role in muscle repair. (source: kirkup-2026-alterations-to-longitudinal-muscle-morphology-and-mechanical-functio.md)
- Resistance training mitigates estrogen deficiency-induced bone deterioration more effectively than aerobic training, increasing osteocyte density, RUNX2 expression, and muscle fiber cross-sectional area in ovariectomized mice. (source: machado-2026-comparing-aerobic-and-resistance-training-in-estrogen-deficiency.md)
- Aging in females is associated with lower estrogen receptor α (ERα) and GPER1 protein expression in skeletal muscle, and lower ER expression is associated with lower eNOS expression, indicating links to nitric oxide-related redox regulation. (source: tamariz-ellemann-2026-aging-is-associated-with-altered-estrogen-receptor-express.md)
Non-Hormonal Treatments
- Cognitive Behavioral Therapy (CBT) adapted for menopause (CBT-Meno) can lead to a 30% to 50% reduction in hot flash episodes by addressing the nervous system's stress response. (source: 2026-05-26.md)
- Dual neurokinin receptor antagonists like elinzanetant offer a non-hormonal option for reducing vasomotor symptoms by 74%. (source: 2026-05-26.md)
- The selective NK3R antagonist GS1-144 significantly reduces vasomotor symptoms frequency and severity in postmenopausal Chinese women, with 30 mg twice daily showing significant reductions at weeks 4 and 12, and 60 mg once daily at week 12. No liver safety risks were observed. (source: wang-2026-efficacy-and-safety-of-gs1-144-a-novel-neurokinin.md)
- Elinzanetant (brand name Lynkuet) was approved by the FDA in the second half of 2025 for the treatment of moderate to severe vasomotor symptoms associated with menopause. (source: treadway-2026-the-drug-update-recent-drug-approvals-summer-2026.md)
- Integrative medical group visits for menopause (MENOGAP), co-delivered by a menopause-certified physician and an acupuncturist, were found to be feasible and acceptable in a pilot study. Participants showed statistically significant improvements in menopausal symptoms (Menopause Rating Scale), knowledge, and self-efficacy. This model provides evidence-informed conventional and integrative health education plus acupuncture in a group setting. (source: taylor-swanson-2026-integrative-medical-group-visits-for-menopause-menogap-resul.md)
Sleep and Menopause
- Waking up at 2-3 AM after menopause is linked to hormonal changes affecting the brain and melatonin, as well as cortisol and nighttime anxiety. (source: 2026-04-27-gNHTRoOiB1I.md)
- Higher nighttime vasomotor symptoms frequency was indirectly associated with worse short-term emotional well-being through greater sleep disturbance, but only when vasomotor symptoms and sleep disturbance were measured subjectively. (source: wood-2026-examining-sleep-disturbance-as-a-mediator-of-the.md)
- Sleep disturbances, including fragmented sleep and clinical insomnia, are common in midlife women and may be partly attributed to the menopause transition. They often co-occur with depressive and anxiety symptoms, vasomotor symptoms, substance use, trauma history, and relationship stressors. Chronic sleep disturbance is related to poorer health and productivity. Evidence-based cognitive-behavioral sleep interventions are effective treatments. (source: jakubowski-2026-sleep-disturbances-in-midlife-women-prevalence-correlates-and.md)
Nutrition and Metabolism
- Hormonal changes during perimenopause and menopause impact metabolism, insulin sensitivity, and fat storage, requiring tailored nutritional strategies. (source: 2026-04-30-RQ0PFnzlM-U.md)
- GLP-1 medications are being explored for their potential benefits in managing weight and metabolic changes during menopause. (source: 2026-05-05-WCDcAfxpof8.md)
- Semaglutide, a GLP-1 receptor agonist, induces weight loss in postmenopausal women but also reduces lean body mass; the functional consequences for muscle and sleep-disordered breathing are incompletely understood. Adequate protein intake, micronutrients, and resistance exercise may help preserve musculoskeletal health, though evidence in semaglutide-treated women remains indirect. (source: pereira-2026-semaglutide-in-postmenopausal-women-clinical-implications-for-weigh.md)
- Earlier menopause (≤45 years) is associated with lower lean body mass and higher risk of sarcopenia, particularly in women with higher BMI. (source: jeong-2026-association-of-age-at-menopause-with-lean-body.md)
- Metabolic dysfunction-associated steatotic liver disease (MASLD) severity and higher liver fat content are associated with lower lipoprotein(a) concentrations in postmenopausal females. (source: de-2026-sex-and-menopause-specific-inverse-associations-between-metabolic-dysfun.md)
- Estimated habitual dairy polar lipid intake was positively associated with post-intervention HDL-C concentrations in perimenopause women, though no significant associations were observed for total cholesterol, LDL-C, or triglycerides. (source: aleksejeva-2026-estimated-habitual-dairy-polar-lipid-exposure-and-post-intervent.md)
- The menopause transition is associated with significant increases in LDL-C and triglycerides, along with alterations in HDL-C composition and function, independent of chronological aging. (source: castaneda-2026-dyslipidemia-across-the-menopause-transition-mechanisms-trajector.md)
Diabetes and Menopause
- Type 2 diabetes mellitus (T2DM) is significantly associated with a greater number and severity of menopausal symptoms among Korean midlife women, particularly in the postmenopausal stage, after controlling for confounding variables. (source: yang-2026-association-between-type-2-diabetes-mellitus-and-menopausal.md)
- In a cross-sectional analysis of the BETTER registry, postmenopausal women with type 1 diabetes had higher risks of cardiovascular disease (RR 3.31), neuropathy (RR 2.22), retinopathy (RR 2.20), falls (RR 2.64), and moderate-to-severe depressive symptoms (RR 1.48) compared to premenopausal women with type 1 diabetes, despite similar HbA1c and insulin doses. (source: bonhoure-2026-physical-and-psychosocial-complications-faced-by-postmenopausal-wo.md)
- Endometriosis is associated with a 46% higher risk of type 2 diabetes (aHR 1.46; 95% CI 1.43, 1.50) compared with no endometriosis, with risk varying by subtype. The strongest associations were observed for 'other site' endometriosis (specified site: aHR 2.67; 95% CI 2.51, 2.84; unspecified site: aHR 2.47; 95% CI 2.35, 2.60). Associations were stronger among premenopausal women than postmenopausal women (aHR 1.55; 95% CI 1.50, 1.60) and those with BMI <30 kg/m² (aHR 2.39; 95% CI 2.34, 2.44). (source: fuzak-2026-endometriosis-subtypes-and-risk-of-type-2-diabetes.md)
- A systematic review and meta-analysis found that menopause hormone therapy (MHT) may have effects on metabolic conditions. Among women without type 2 diabetes, MHT use was associated with changes in glucose metabolism and reduced risk of new-onset type 2 diabetes. Among women with type 2 diabetes, MHT use affected glucose, insulin, lipid, and blood pressure levels. (source: liang-2026-menopause-hormone-therapy-and-type-2-diabetes-risk.md)
Testosterone Therapy
- Transdermal testosterone significantly improved sexual desire and satisfaction in postmenopausal women with hypoactive sexual desire disorder, though compounded formulations showed variable hormone levels. (source: CeccattoAndrade2026-transdermal-testosterone-desire.md)
- Brazilian gynecologists widely prescribe testosterone therapy (TT) for hypoactive sexual desire disorder (95%) and other indications, with 93.9% prescribing compounded gels or creams, 54.9% implants, and 38% using gels for males. Most (78.1%) believe treatment should last up to 6 months, and 91.2% believe adverse effects sometimes occur. (source: valadares-2026-a-survey-of-brazilian-gynecologists-prescribing-practices-and.md)
- Of 1,213 Brazilian gynecologists surveyed, 85.6% aimed for TT to reach the reference range for premenopausal women, and 66% agreed or partially agreed to prescribe for breast cancer patients. (source: valadares-2026-a-survey-of-brazilian-gynecologists-prescribing-practices-and.md)
- The survey highlights a critical need for approved, standardized testosterone therapy options for women, as current practice relies heavily on compounded and unapproved formulations that risk supraphysiological levels. (source: valadares-2026-a-survey-of-brazilian-gynecologists-prescribing-practices-and.md)
Gut and Immune Health
- The menopause transition is associated with rising markers of compromised gut barrier integrity (FABP2, sCD14), suggesting a pathway for inflammation similar to animal models. (source: shieh-2026-markers-of-compromised-gut-epithelial-barrier-integrity-increase.md)
- Lifetime endogenous hormone exposure is associated with lower CD8+ T cell density in breast tumors, potentially influencing immune responses to cancer. (source: zhang-2026-association-between-cumulative-lifetime-exposure-to-reproductive-horm.md)
- Serum I-FABP levels are significantly higher in menopausal women compared to non-menopausal controls, suggesting compromised gut barrier integrity likely related to estrogen deficiency. Elevated I-FABP was associated with a 22.7-fold increased likelihood of menopause. (source: keskino-lu-2026-serum-intestinal-fatty-acid-binding-protein-as-a-biomarker.md)
- Co-supplementation of fructooligosaccharide (FOS) with soy isoflavone (SIF) in an estrogen-deprived rat model synergistically improved gut-brain axis function by modulating the gut microbiome, reducing oxidative stress and inflammation in the hippocampus and colon, and selectively activating ER-β expression without affecting serum estradiol or uterine weight. (source: chaudhary-2026-co-supplementation-of-fructooligosaccharide-with-soy-isoflavone-r.md)
Probiotics and Menopause
- A probiotic formula containing Levilactobacillus brevis KABP052, Lactiplantibacillus plantarum KABP051, and Pediococcus acidilactici KABP021 (1×10^9 CFU/day) was associated with improvements in menopause-associated symptoms and quality of life in perimenopausal and postmenopausal women, according to a randomized double-blind placebo-controlled trial. (source: rodr-guez-palmero-2026-efficacy-of-a-probiotic-formula-in-the-management.md)
- In an ovariectomized rat model of postmenopausal bone loss, a combination of the probiotic Lactobacillus casei (LC) and the microalga Chlorella vulgaris (CV) demonstrated significantly greater restoration of serum calcium and normalization of alkaline phosphatase (ALP) levels compared with monotherapies. The combination also produced the most pronounced increases in bone mineral density (BMD) and bone mineral content (BMC) at all skeletal sites, suggesting a promising multi-targeted natural strategy for postmenopausal osteoporosis. (source: gholami-2026-prospective-efficacy-of-a-novel-dual-pronged-strategy-combining.md)
Surgical Menopause
- Surgical menopause shows more pronounced early deterioration in left ventricular function (measured by LV GLS) compared to natural menopause, though differences may normalize by 6 months. (source: yaz-c-2026-early-subclinical-left-ventricular-dysfunction-after-surgical-menopau.md)
- Surgical menopause is associated with higher symptom severity and cumulative burden than natural menopause across multiple domains. (source: aggarwal-2026-multidimensional-menopausal-symptom-burden-in-singapore-marie.md)
Early Life Factors and Menopause
- Antenatal corticosteroid (ANS) exposure and LPS-induced chorioamnionitis induce acute molecular and structural changes in the developing fetal ovary, with potential implications for ovarian reserve and reproductive lifespan. (source: seah-2026-chorioamnionitis-and-glucocorticoids-elicit-acute-adverse-effects-on.md)
Neurological Conditions and Menopause
- Parkinson's disease differs between women and men in epidemiology, clinical manifestations, and treatment response, with sex hormones potentially modulating dopaminergic and neuroinflammatory circuits. The role of estradiol exposure and menopausal hormone therapy in disease progression warrants further study. (source: boone-2026-parkinson-s-disease-across-female-reproductive-stages-clinical-implic.md)
- Combined menopausal HRT (estrogen-progestin) was associated with an increased risk of Parkinson's disease (RR 1.40; 95% CI 1.07-1.82), while estrogen-only therapy showed no significant association (RR 1.01; 95% CI 0.81-1.27). (source: macedo-2026-differential-effects-of-hormone-therapy-formulations-on-parkinson-s.md)
Iron Metabolism and Menopause
- Macrophagic myofasciitis (MMF) may involve genetic susceptibility affecting iron regulation (TFR2, SLC40A1) and macrophage function, with potential implications for aluminum adjuvant persistence and menopausal iron dysregulation. (source: le-2026-macrophagic-myofasciitis-associated-with-transferrin-receptor-2-and.md)
Social Determinants of Health
- Lower education level, lower poverty income ratio (PIR), and renting a home were significantly associated with a shorter reproductive lifespan in women, affecting menopause timing. (source: li-2026-cumulative-social-determinants-of-health-and-reproductive-lifespan.md)
- Higher cumulative social disadvantage, including factors like food security and housing status, was associated with a shorter reproductive lifespan among women, with implications for menopause onset. (source: li-2026-cumulative-social-determinants-of-health-and-reproductive-lifespan.md)
- In a predominantly Hispanic population on the US-Mexico border, menopausal symptoms (especially sleep disturbances and weight gain) were common, yet 58% reported symptoms had never been addressed by a clinician. Younger age, higher education, and non-Hispanic ethnicity were associated with more treatment engagement, highlighting socioeconomic and ethnic disparities in menopause care. (source: mcferren-2026-evaluating-menopausal-symptom-burden-and-treatment-engagement-in.md)
- A cross-sectional study in northwest Iran found mean age at natural menopause (ANM) was 49.98 ± 2.62 years. Significant associations were found between menopause age and BMI (p=0.001), number of abortions (p=0.043), breastfeeding duration (p=0.006), gravidity (p=0.030), and contraceptive use (p=0.050). Lifestyle score showed a positive correlation with menopause age (p=0.001). Multivariable regression identified BMI and lifestyle dimensions (weight control, nutrition, psychological, spiritual, social, environmental health, accident prevention) as significant predictors of ANM. (source: gholampour-nooran-2026-age-at-natural-menopause-and-associated-lifestyle-and.md)
Kidney Health
- Premature menopause (before age 40) was associated with a 50% higher odds of kidney stone disease (KSD) in two large cohorts, with HRT use partially attenuating but not eliminating the elevated risk. (source: usman-2026-premature-menopause-and-risk-of-kidney-stone-disease.md)
- Genetic predisposition further increased the hazard of KSD in women with premature menopause, with polygenic risk scores showing a dose-response relationship. (source: usman-2026-premature-menopause-and-risk-of-kidney-stone-disease.md)
Chronic Kidney Disease and Reproductive Health
- Chronic kidney disease (CKD) disrupts reproductive physiology through hypothalamic-pituitary-ovarian axis dysfunction, hyperprolactinemia, diminished ovarian reserve, and chronic inflammation, leading to menstrual irregularities, premature menopause, and sexual dysfunction. Many nephrologists feel ill-equipped to counsel on reproductive decision-making, and early consideration of fertility preservation strategies (e.g., GnRH agonists, oocyte cryopreservation) is important. (source: bhaduri-2026-female-reproductive-health-in-kidney-disease.md)
Pelvic Health
- Vaginal bulge is the most common symptom of pelvic organ prolapse (POP), with stress urinary incontinence and pain being more bothersome in younger women (<50 years) compared to older women (≥70 years). (source: dunn-2026-perception-of-prolapse-associated-symptoms-by-age-a-cross-sectional.md)
- Dyspareunia in perimenopause and postmenopausal women is common and often undertreated, with genitourinary syndrome of menopause (GSM) being a frequent contributor. Management includes education, moisturizers, lubricants, and prescription therapy for GSM, usually low-dose vaginal estrogen. (source: broul-2026-assessment-and-management-of-dyspareunia-in-peri-and.md)
- Vaginitis is an incredibly common problem among women globally, with traditional therapies like antibiotics and antifungals effective but often requiring prolonged suppressive therapy due to recurrence. Newer therapies include partner treatment and adjunctive therapies like vaginal pH-modulating topicals. (source: mckinney-2026-evaluation-of-vaginitis-and-its-treatment.md)
- Menopause plays a key role in anal incontinence through hypoestrogenism-related changes in pelvic floor musculature, connective tissue integrity, and sphincter function, affecting approximately 2-21% of women with prevalence increasing after menopause. (source: ozcivit-2026-anal-incontinence-and-menopause.md)
- Radiofrequency therapy for genitourinary syndrome of menopause (GSM) shows significantly greater improvement in sexual function (FSFI score) compared to vaginal estrogen and placebo/moisturizer, but is comparable to laser therapy. Vaginal health outcomes are similar across all comparators, and adverse events are exclusively mild. (source: lumowa-2026-efficacy-and-safety-of-radiofrequency-as-a-treatment.md)
- In breast cancer survivors on aromatase inhibitors, vaginal estrogen provides greater improvement in vaginal dryness and dyspareunia than non-hormonal moisturizer, with minimal systemic estrogen exposure in most patients. (source: niravath-2026-vemora-vaginal-estrogen-versus-non-hormonal-moisturizer-in-women.md)
- Body image concerns are strongly negatively correlated with sexual self-efficacy and sexual function in postmenopausal women, suggesting that estrogen-related changes and psychological factors interact to affect sexual health. (source: aliaghdami-2026-body-image-concerns-and-their-association-with-sexual.md)
- Fractional carbon dioxide vaginal laser (fCO2) therapy for genitourinary syndrome of menopause (GSM) showed significant and durable improvement in urgency and overactive bladder symptoms out to 36 months, with 44.7% of women reporting being markedly or moderately better at 36 months on the PGI-I. (source: zwaans-2026-fractional-carbon-dioxide-vaginal-laser-for-the-treatment.md)
- Photobiomodulation (PBM) combined with pelvic floor muscle training (PFMT) significantly improved sexual function (FSFI total score) and showed clinically significant improvement in urinary function (ICIQ-SF) compared to PFMT+sham PBM in women with genitourinary syndrome of menopause. (source: oliveira-2026-photobiomodulation-and-pelvic-floor-training-for-genitourinary-syn.md)
- Vaginal mesh hysteropexy and hysterectomy with uterosacral ligament suspension provide similar economic value for symptomatic uterovaginal prolapse. While hysteropexy had a lower failure rate through 5 years, costs and quality-adjusted life years were not significantly different between the two surgical treatments. (source: harvie-2026-cost-effectiveness-of-vaginal-mesh-hysteropexy-versus-hysterectomy-u.md)
- Myomatous erythrocytosis syndrome (MES) is a rare condition where erythrocytosis associated with a uterine leiomyoma resolves after tumor removal. A case report describes a 55-year-old woman with an 8-kg uterine leiomyoma and marked erythrocytosis (hemoglobin 20.1 g/dL) that resolved after hysterectomy, with postoperative normalization of serum erythropoietin. (source: ida-2026-myomatous-erythrocytosis-syndrome-associated-with-an-8-kg-uterine.md)
- A novel EFNA3-mimetic agonist peptide (EFNA3-MAP) that engages the EphA2 receptor restores desmoglein-1 (DSG1) expression and vaginal epithelial thickness in DMPA-treated mice and rhesus macaques, and reduces susceptibility to genital infections, highlighting ephrin-Eph signaling as a key regulator of vaginal stratified squamous epithelium barrier function. This has potential implications for vaginal health in menopause-related estrogen deficiency. (source: vicetti-2026-targeting-epha2-with-a-novel-efna3-mimetic-peptide-enhances.md)
Perimenopause Awareness
- 34% of US women aged 35+ reported uncertainty about their reproductive stage, peaking at 42% among those aged 40-44, with symptom confusion and attribution being the most common driver of uncertainty. (source: xu-2026-exploring-prevalence-and-drivers-of-perimenopause-uncertainty-among.md)
- Barriers to confirmation and care, including dismissive healthcare encounters, contributed to perimenopause uncertainty, particularly in women aged 40-44. (source: xu-2026-exploring-prevalence-and-drivers-of-perimenopause-uncertainty-among.md)
Digital Health Tools
- Menopause apps are experiencing a commercial boom, offering empowerment but also posing risks due to variable quality and potential misinformation. (source: glauser-2026-menopause-apps-offer-empowerment-but-pose-risks.md)
Epigenetics and Menopause
- Menopause leads to significant epigenetic transformations, including changes in DNA methylation, histone modifications, and microRNA expression, which can alter gene expression and increase susceptibility to chronic diseases like cardiovascular disease, osteoporosis, and hormone-related cancers. (source: zdemir-2026-menopause-and-epigenetic-changes-a-review.md)
Bone Health
- Biomass-derived humic acid (HA) mitigates metabolic dysfunction and bone loss from estrogen deficiency, supporting its potential as adjunct therapy. (source: andrade-2026-humic-acid-from-biomass-attenuates-ovariectomy-induced-metabolic-an.md)
- Women have higher incidence of hip fractures than men due to accelerated bone loss after menopause and higher incidence of falls. Other risk factors include low bone mineral density, prior fracture, and factors contributing to falls. (source: johannesdottir-2026-hip-fractures-a-review.md)
- In calcium-replete older women, calcium supplements had little effect on the response to antiresorptives, whereas low protein intake blunted their benefits. (source: papageorgiou-2026-dietary-and-supplemental-calcium-intake-and-bone-changes.md)
- Pregnancy- and lactation-associated osteoporosis (PLO) is a syndrome characterized by fragility fractures (most commonly vertebral, often multiple) occurring in late pregnancy or the early postpartum period. (source: hadji-2026-pregnancy-and-lactation-associated-osteoporosis-a-position-statement.md)
- A Transformer-LSTM hybrid model identified total type 1 collagen N-terminal propeptide (TP1NP) as the most critical physiological indicator affecting abnormal bone mineral density in perimenopausal women, with factors like educational level, body weight, and menopause before age 45 also exerting significant influence. The top 25 core features could explain 80% of the associated osteoporosis risk. (source: hu-2026-identification-and-importance-analysis-of-osteoporosis-risk-factors.md)
- Bone health literacy among breast cancer patients in perimenopause and early postmenopause is suboptimal; osteoporosis self-efficacy partially mediates the relationship between risk perception and bone health literacy, suggesting targets for intervention. (source: gai-2026-bone-health-literacy-and-risk-perception-in-perimenopausal.md)
- Management of chronic hypoparathyroidism and hyperparathyroidism in pregnancy and lactation requires intensive surveillance, with conventional therapy (activated vitamin D and calcium) continued throughout pregnancy but dosages may change unpredictably. For primary hyperparathyroidism, surgical treatment is recommended before conception, and parathyroidectomy in the second trimester for calcium above 2.85 mmol/L. (source: pilz-2026-management-of-chronic-hypoparathyroidism-and-hyperparathyroidism-in-pr.md)
- Strontium ranelate (SrR), used for postmenopausal osteoporosis, showed clastogenic and aneugenic effects in Allium cepa and toxic effects in Artemia salina assays, but co-treatment with resveratrol (RSV) reduced DNA damage, demonstrating antigenotoxic potential. (source: beir-o-2026-toxicological-and-cytogenetic-screening-of-strontium-ranelate-alone.md)
- L1 vertebral attenuation ≤160 HU on 100-kVp low-dose computed tomography (LDCT) identified postmenopausal women at three-fold higher fragility fracture risk, with performance comparable to the Fracture Risk Assessment Tool without BMD. In a healthy screenee cohort, L1 HU serves as the primary bone health signal, enabling early identification of at-risk individuals within existing LDCT workflows at no additional cost. (source: lin-2026-opportunistic-l1-attenuation-on-100-kvp-ldct-predicts-ten-year.md)
- CKD-associated osteoporosis in patients with CKD G4-5D requires a pragmatic treatment approach: optimize mineral metabolism including parathyroid hormone targeting before initiating bone-targeting drugs, and consider lifestyle modification. (source: evenepoel-2026-ckd-associated-osteoporosis-in-patients-with-ckd-g4-5d-a.md)
- Enhanced bioavailability vitamin D formulations (liposomal vitamin D3) significantly improved bone mineral density at femoral neck and lumbar spine, reduced bone turnover markers, and showed fewer fragility fractures compared to conventional cholecalciferol in postmenopausal women. (source: rasool-2026-vitamin-d-supplementation-and-bone-health-in-post-menopausal.md)
- Osteoporosis is a silent disease disproportionately affecting women during peri- and postmenopause due to oestrogen reduction causing resorption-formation uncoupling. Incidence is increasing. Screening to prevent fractures is essential, especially with prior fracture as the biggest risk factor. Diagnosis is by DXA T-score ≤ -2.5. X-rays can complement because a fragility fracture substantiates a diagnosis. (source: sztal-mazer-2026-menopause-and-osteoporosis-epidemiology-pathophysiology-screeni.md)
- Risk stratification for osteoporosis integrates fracture history, bone density, and FRAX risk. Non-pharmacological management includes adequate calcium intake and vitamin D sufficiency. HRT (MHT) should be considered in women aged <65 years with T-scores between -1.8 and -2.5. Pharmacotherapy is integral for fracture prevention; those at very high fracture risk may need referral for bone anabolic therapy. (source: goeltom-2026-menopause-and-osteoporosis-non-pharmacological-and-pharmacological.md)
- Higher total abdominal muscle area (TAMA) at the L3 vertebral level on CT was independently associated with a lower risk of osteoporosis in postmenopausal Korean women (adjusted OR 0.365). This highlights the importance of muscle mass assessment in bone health evaluation. (source: lee-2026-the-association-between-abdominal-muscle-mass-quantified-by.md)
- Sclerostin, an antagonist of the Wnt/β-catenin signaling pathway, shows a positive association with bone mineral density in chronic spinal cord injury but not in acute injury. Pharmacological inhibition of sclerostin is promising but requires more research, particularly in postmenopausal females and pediatric populations. (source: stoikos-2026-the-role-of-sclerostin-in-spinal-cord-injury.md)
- Yishen Gushu Formula (YSGSF) partially improved cortical structure and trabecular continuity in ovariectomized rats. Proteomic analysis identified three core proteins (RNASE3, DDX54, MINDY2) suggesting regulation of nitrogen metabolism, circadian rhythm, extracellular matrix remodeling, and lipid metabolism as mechanisms against postmenopausal osteoporosis. (source: yongjin-2026-proteomics-based-analysis-of-the-therapeutic-mechanism-of.md)
- Yishen Gushu Formula (YSGSF) attenuates bone loss in ovariectomized rats by downregulating key genes in the B-cell receptor signaling pathway (CD79A, CD79B, VPREB1, VPREB3), improving the skeletal immune microenvironment. (source: jin-2026-yishen-gushu-formula-attenuates-ovariectomy-induced-bone-loss-by.md)
- Neddylation of NFATc1 and Runx2 regulates osteoclast-osteoblast balance and represents a dual-action therapeutic target for postmenopausal osteoporosis. (source: lee-2026-neddylation-of-nfatc1-and-runx2-regulates-osteoclast-osteoblast-balance.md)
- There is no significant association between low bone mineral density and hearing loss in premenopausal females. (source: howe-2026-hearing-loss-and-low-bone-mineral-density-in.md)
- RARRES2 deficiency inhibits postmenopausal osteoporosis by promoting ferroptosis-mediated osteoclast differentiation via Nrf2/GPX4 axis inhibition. (source: wang-2026-rarres2-deficiency-inhibits-postmenopausal-osteoporosis-by-promoting-f.md)
- Cellular senescence and the senescence-associated secretory phenotype (SASP) in the bone microenvironment contribute to age-related bone loss by promoting resorption and suppressing formation via RANKL/OPG, Wnt/β-catenin, and NF-κB pathways. Clearance of senescent cells prevents bone loss in mice, indicating SASP as a distinct contributor to skeletal ageing. (source: liu-2026-cellular-senescence-and-the-sasp-in-skeletal-ageing.md)
- A physiology-based mathematical model of the renin-angiotensin system (RAS), bone remodeling, and calcium homeostasis demonstrates how estrogen decline at menopause increases bone resorption and osteoporosis risk. The model also shows that RAS inhibitors may interact with estrogen pathways, providing a framework for understanding crosstalk between cardiovascular and bone health in postmenopausal women. (source: stadt-2026-a-physiology-based-mathematical-model-of-the-renin-angiotensin-system.md)
- Surface-engineered phytochemical nanomedicines, incorporating mineral-affinity, cell-affinity, and pathology-responsive modules, are being developed to overcome delivery barriers for plant-derived compounds (flavonoids, isoflavones, curcuminoids, stilbenes) in treating postmenopausal osteoporosis. These nanocarriers aim to improve bone-associated distribution, local retention, and microenvironment-responsive release, with multimodal imaging-based evaluation of therapeutic outcomes. (source: gao-2026-surface-engineered-phytochemical-nanomedicines-for-postmenopausal-osteo.md)
- Nuciferine, an aporphine alkaloid from lotus leaf, ameliorates bone loss in ovariectomized rats by activating the TFEB-mediated autophagy-lysosomal pathway, promoting osteogenic differentiation of BMSCs. It increased bone mineral density (BMD), improved bone microarchitecture, and upregulated bone formation markers while downregulating resorption markers. (source: shi-2026-nuciferine-ameliorates-ovariectomy-induced-bone-loss-via-tfeb-mediated.md)
- The Osteoporosis Self-Assessment Tool for Asians (OSTA) was originally developed for postmenopausal Asian women, but its performance in men requires age-specific cutoff values, and it showed comparable fracture prediction to FRAX in elderly Japanese men. (source: fujita-2026-performance-of-screening-tools-for-osteoporosis-and-fractures.md)
- Baicalein, a natural flavonoid, ameliorates postmenopausal osteoporosis with iron accumulation by inhibiting osteoclastogenesis via Nrf2 activation. In vitro, baicalein suppressed osteoclast differentiation, reduced iron content and ROS, and upregulated Nrf2 nuclear translocation. In an ovariectomized mouse model with iron overload, oral baicalein prevented bone loss, improved microarchitecture, reduced iron deposition, and activated Nrf2 signaling; co-administration of an Nrf2 inhibitor reversed these effects, suggesting baicalein as a multi-target candidate for PMOP with iron accumulation. (source: guo-2026-baicalein-ameliorates-postmenopausal-osteoporosis-with-iron-accumulatio.md)
- In a Singapore study of 318 postmenopausal women (mean age 68, mean baseline BMD T-score -1.9 lumbar spine, -2.4 femoral neck, -2.1 total hip), 3 years of denosumab therapy resulted in mean BMD increases of 6.95% at the lumbar spine, 3.89% at the femoral neck, and 4.77% at the total hip. Lower baseline T-scores and higher BMI were associated with greater response. Musculoskeletal pain was the most common adverse event (6%); one case of osteonecrosis of the jaw occurred in a patient with prior alendronate exposure. (source: chua-2026-prospective-observational-study-of-denosumab-in-postmenopausal-women.md)
Quality of Life
- Early postmenopause is a vulnerable period for impaired quality of life, with vasomotor and urogenital symptoms being important correlates of poorer well-being. (source: nasreen-2026-assessing-the-burden-of-menopausal-symptoms-and-their.md)
- In a cohort of 557 midlife Chinese women, earlier menopause and shorter reproductive life span were associated with higher adjusted sexual-domain scores on the Menopause-Specific Quality of Life (MENQOL) questionnaire, with significant differences for menopause before age 45 years (β = 0.83, 95% CI: 0.21, 1.44) and reproductive life span <30 years (β = 0.98, 95% CI: 0.21, 1.74). These sexual-domain associations were attenuated after adjustment for time since menopause, whereas associations with higher vasomotor symptoms (VMS) scores became apparent in postmenopausal analyses. (source: xie-2026-menarche-menopause-reproductive-life-span-and-menopause-specific-qualit.md)
Voice and Menopause
- Voice changes during menopause manifest as functional and work-related limitations, with the Menopausal Voice-Related Work Limitation Scale (MenoVWL-TR) being a valid and reliable tool for assessing these changes. (source: arslan-sar-mehmeto-lu-2026-menopausal-voice-related-work-limitation-scale-validi.md)
Treatment Preferences
- Women value safe and efficacious treatment for vasomotor symptoms, with high importance on avoiding long-term risks like blood clots and breast cancer. Reducing vasomotor symptoms frequency mattered over and above wider menopause symptoms, though treatment priorities were highly individual. (source: heidenreich-2026-women-s-treatment-preferences-for-moderate-to-severe-vasomotor.md)
Cardiovascular Health
- Heart failure and menopause commonly coexist in middle-aged women, but overlapping symptomatology often complicates diagnosis. Oestrogen exerts cardioprotective effects through anti-inflammatory and vasodilatory pathways and its decline has been proposed as a mechanistic explanation for myocardial fibrosis and diastolic dysfunction. (source: kwan-2026-overlap-between-heart-failure-and-menopause-diagnostic-challenges.md)
- Many women have suboptimal cardiovascular health (CVH), which declines during midlife. Few studies have characterized CVH across the menopausal transition or identified its sociodemographic and neighborhood determinants. (source: lin-2026-associations-of-sociodemographic-and-neighborhood-vulnerability-with-ca.md)
- Progesterone stimulates vasoactive factors, modulates lipid profiles, reduces inflammatory responses, inhibits platelet aggregation and cell proliferation, and lowers blood pressure, thereby contributing to the reduction of cardiovascular disease risk. (source: dos-2026-progesterone-and-vascular-function-mechanisms-and-therapeutic-implicati.md)
- Coronary microvascular dysfunction (CMD) is a central pathophysiological mechanism in heart failure with preserved ejection fraction (HFpEF), disproportionately affecting females, especially after menopause. Females exhibit distinct inflammatory and metabolic profiles, accelerated vascular and ventricular stiffening, and higher prevalence of CMD in the absence of obstructive coronary artery disease. (source: roy-2026-a-sex-specific-perspective-on-coronary-microvascular-dysfunction-in.md)
- Race differences in vascular health persist after adjusting for reproductive history in midlife women, according to a SWAN Study analysis. Non-Hispanic Black (NHB) women exhibit greater pulse pressure, estimated pulse wave velocity, and estimated vascular overload index compared with non-Hispanic White (NHW) women, and these differences are not explained by reproductive history or traditional risk factors. (source: tharpe-carter-2026-race-differences-in-vascular-health-persist-after-adjustment.md)
- Coexisting premature menopause (before age 40) and hypertension confer a markedly elevated risk of cardiovascular disease events (HR 1.64) compared with either factor alone, from a nationwide Korean cohort. (source: choi-2026-premature-menopause-and-hypertension-as-combined-risk-factors.md)
- A case report of a 72-year-old postmenopausal woman with ischemia and nonobstructive coronary arteries (INOCA) demonstrated that recurrent coronary vasospasm can lead to focal myocardial fibrosis and a hyperdynamic small left ventricle with supranormal ejection fraction, increasing risk of diastolic dysfunction and heart failure. (source: nguyen-2026-focal-myocardial-fibrosis-mimicking-hypertrophy-in-inoca-and.md)
- The menopause transition marks a period of accelerated cardiovascular risk, with ovarian ageing independently associated with adverse lipid profiles, fat redistribution, vascular dysfunction, and metabolic syndrome. Early, premature, surgical, and symptomatic menopause further amplify risk. Lifestyle optimization and lipid-lowering therapy remain powerful strategies. HRT is not recommended solely for primary or secondary CVD prevention, but may be offered for symptom management and bone protection in appropriately selected women, especially in cases of premature, early, or surgical menopause. (source: burns-2026-menopause-cardiovascular-health-and-the-role-of-hormone.md)
- In an ovariectomized rat model of estrogen deficiency, the SGLT2 inhibitor empagliflozin significantly improved endothelial function, enhanced eNOS activation, and restored nitric oxide levels, with effects comparable to estradiol. This suggests empagliflozin as a potential non-hormonal therapeutic strategy for endothelial dysfunction in postmenopausal conditions. (source: mad-2026-empagliflozin-improves-endothelial-function-in-an-ovariectomized-rat.md)
- In patients with inflammatory arthritis (IA) aged >40, sex and menopausal status are associated with coronary and extra-coronary CT abnormalities. CAC ≥100 occurred in 28% of males, 20% of postmenopausal females, and 1.4% of premenopausal females. Postmenopausal females had more aortic calcification and aortic enlargement. Independent predictors of CAC ≥100 included older age, higher CRP, and smoking. (source: mohammed-2026-sex-and-menopausal-status-differences-in-coronary-calcification.md)
- In postmenopausal women aged 50-69, abdominal obesity with hypertension is characterized by impaired forearm muscle microvascular reactivity, greater arterial stiffness (carotid-femoral pulse wave velocity), and increased aortic pressures. Microvascular function was inversely associated with visceral adipose tissue, aortic stiffness, and aortic pressures. (source: figueroa-2026-muscle-microvascular-reactivity-and-its-associations-with-arterial.md)
- Serum uric acid (SUA) levels in women are influenced by hormonal status, age, and menopause, with a sharper increase after midlife. Women may experience cardiovascular risk at lower SUA concentrations than men, and SUA should be interpreted as a sex-sensitive cardiometabolic biomarker rather than a fixed threshold. Prospective studies are needed to validate sex-, age-, and hormone-specific SUA thresholds for cardiovascular prevention. (source: mattioli-2026-time-to-redefine-serum-uric-acid-levels-in.md)
- Association between endogenous sex hormones and cardiovascular-kidney-metabolic in US adults has been demonstrated in a population-based study. (source: xie-2026-association-between-endogenous-sex-hormones-and-cardiovascular-kidney-m.md)
- In a community-based Korean cohort, urinary albumin-to-creatinine ratio (UACR) within the normal range (<30 mg/g) was significantly associated with incident cardiovascular disease in postmenopausal women (adjusted HR 1.09 per 1 mg/g increase), but not in men or premenopausal women, suggesting low-grade albuminuria as an early biomarker of cardiovascular risk in postmenopausal women. (source: ko-2026-urinary-albumin-to-creatinine-ratio-and-risk-of-incident-cardiovascular.md)
Aging and Super-Enhancers
- Super-enhancers play a pivotal role in aging and aging-related diseases by modulating key biological processes, including cell proliferation, differentiation, and senescence. Dysregulation of super-enhancers contributes to age-related disorders like atherosclerosis and type Ⅱ diabetes. (source: wang-2026-from-cell-to-disease-regulatory-networks-and-mechanisms.md)
Menstrual Cycle Disorders
- Sports physicians often lack systematic approaches to screening and managing menstrual cycle disorders in female athletes, with only 55.8% consistently assessing menstrual status and 34.1% evaluating menstrual regularity. Hormonal treatment is rarely prescribed, and many physicians express interest in standardized screening tools. (source: ducamp-2026-screening-and-management-of-menstrual-cycle-disorders-in.md)
Hypopituitarism
- Hypopituitarism is a rare but treatable complication of severe Russell's viper envenomation, with symptoms including secondary adrenal insufficiency, hypogonadotropic hypogonadism, and central hypothyroidism. Hormone replacement therapy can significantly improve clinical outcomes. (source: mohammed-2026-hypopituitarism-following-russell-s-viper-envenomation-in-banglade.md)
Endocrine Updates
- The 13th Annual EndoBridge Meeting highlighted contemporary approaches to managing acromegaly, subclinical thyroid dysfunction, osteoporosis, and hormonal treatment strategies for menopause and premature ovarian insufficiency. (source: yildiz-2026-endobridge-2025-pearls-and-highlights.md)
Sleep Apnea and Bladder Health
- Obstructive sleep apnea (OSAS) is associated with overactive bladder (OAB) through mechanisms like intermittent hypoxia and autonomic nervous system dysregulation. Female-specific factors such as menopause and estrogen deficiency may amplify bladder symptoms. (source: batur-2026-obstructive-sleep-apnea-syndrome-and-overactive-bladder-expanding.md)
- A fear-avoidance model proposes that urinary urgency in overactive bladder (OAB) can trigger a self-sustaining cycle of avoidance and hypervigilance; menopause is identified as a physiological cause of OAB where fear-avoidance acts as a secondary amplifier. (source: patel-2026-fear-avoidance-and-overactive-bladder-toward-a-mechanism-informed-mod.md)
Bone Health Awareness
- Women aged 40-65 with limited income in Shanghai have limited bone-health knowledge and preventive practices, despite considering bone health important. Higher educational attainment and regular physical activity are associated with slightly higher knowledge scores. (source: zhou-2026-what-are-the-attitudes-awareness-levels-and-practices.md)
Endometriosis and Menopause
- Most postmenopausal women with endometriosis are asymptomatic (55.7%), but a small subset may have ectopic implants that remain biologically active and progress to malignant precursor forms. Pelvic or abdominal pain is the most common symptom among symptomatic women. (source: fitas-2026-menopause-and-endometriosis-symptoms-and-risk-of.md)
- Postmenopausal endometriosis appears to confer an increased risk of ovarian carcinoma, particularly ovarian clear cell carcinoma (OCCC) and ovarian endometrioid carcinoma (OEC). (source: fitas-2026-menopause-and-endometriosis-symptoms-and-risk-of.md)
Testosterone-to-Estradiol Ratio
- In postmenopausal women with HFpEF, a lower testosterone-to-estradiol ratio (T/E2) is associated with greater systemic inflammation, worse diastolic hemodynamics, and higher odds of short-term clinical events, suggesting T/E2 may serve as a candidate endocrine-inflammatory marker for HFpEF phenotyping. (source: qi-2026-association-of-testosterone-to-estradiol-ratio-with-inflammation-and-cli.md)
Reproductive Lifespan in Cancer Survivors
- Anti-Müllerian hormone (AMH) levels decline significantly after cancer treatment but improve between 6 and 12-24 months post-treatment. Long-term AMH trajectories in cancer survivors align with age-matched healthy controls, indicating similar reproductive aging patterns. (source: balachandren-2026-assessing-the-reproductive-lifespan-of-female-cancer-survivors.md)
Premature Ovarian Insufficiency
- Premature menopause (POI) confronts women with menopause before age 40, creating temporal dislocation where bodies age 'out of sync' with chronological age and social environment, leading to internalized ageism. (source: budke-2026-out-of-time-out-of-place-temporal-desynchronization.md)
- Healthcare encounters for POI are frequently marked by misrecognition and epistemic injustice as it falls outside age-normative clinical expectations. (source: budke-2026-out-of-time-out-of-place-temporal-desynchronization.md)
Ovarian Aging and Immunity
- The immune system plays a dual role in ovarian aging, regulating both physiological age-related decline and pathological accelerated aging such as premature ovarian insufficiency (POI). Age-related immunosenescence and chronic low-grade inflammation (inflammaging) coordinately drive ovarian dysfunction. Therapeutic strategies targeting immune regulation may offer new avenues for preserving ovarian function and delaying menopause. (source: wang-2026-decoding-the-immune-regulation-of-ovarian-aging-mechanisms.md)
Cancer Survivors and Menopause
- Menopausal symptoms are common after cancer treatment, with wide-ranging impacts on cancer survivors' daily living. Cancer survivors have unmet needs in treatment, support, and information for managing menopausal symptoms. Between 26 and 80% were untreated or self-managing their symptoms, 15-76% found their treatments ineffective, and 23-68% desired additional treatment. (source: serwaa-2026-a-mixed-studies-systematic-review-of-the-unmet.md)
- Among endometrial cancer survivors aged 18-51, short-term use of vaginal estrogen therapy was not associated with an increased risk of cancer recurrence (HR 0.87; 95% CI 0.60-1.27), suggesting it may be a safe option for managing genitourinary symptoms. (source: hsu-2026-vaginal-estrogen-therapy-utilization-and-associated-outcomes-in.md)
Cancer and Cardiovascular Disease
- Mortality from both gynecologic cancer and cardiovascular disease (CVD) in US women aged ≥25 years showed a 49.0% increase in total deaths from 1999 to 2023, though the overall age-adjusted mortality rate remained stable. Mortality was highest among women aged ≥85 years, with a marked rise after 2018. Non-Hispanic Black women and non-metropolitan residents consistently had the highest mortality. (source: liu-2026-mortality-trends-in-us-patients-with-gynecologic-cancer.md)
Cervical Cancer Screening
- An interpretable machine learning (ML) tool for cervical cancer screening achieved a clinical sensitivity of 92.5% for detecting high-grade squamous intraepithelial lesions or worse (HSIL+), significantly outperforming manual methods (84.2%). Menopausal tissue atrophy or active vaginal infections caused no significant performance degradation. The ML system compressed median slide-review time by 63.0% and increased daily screening capacity by 175%. (source: chang-2026-an-explainable-machine-learning-approach-for-cervical-cancer.md)
Endometrial Cancer Screening
- Black women have significantly lower completion rates for transvaginal ultrasound for endometrial cancer screening compared with White women (75.7% vs 88.9%), primarily due to fibroids impairing endometrial visibility; however, when completed, the test retains excellent accuracy for excluding cancer. (source: rotenberg-2026-racial-differences-in-sonographic-evaluation-in-suspected-cases.md)
Chronic Low Back Pain
- The Integrated Resilience Method, a six-pillar framework for women 50+ with chronic low back pain (CLBP), addresses biopsychosocial factors including hormonal change, sarcopenia, sleep disruption, fear-avoidance, and caregiving stress. The framework prioritizes exercise, pain education, and self-efficacy as the strongest evidence-based components, with nutrition and stress-resilience practices as adjunct supports. (source: padernal-2026-the-integrated-resilience-method-a-whole-person-framework-for.md)
Hypothyroidism and Relaxation
- Progressive muscle relaxation (PMR) significantly reduced fatigue and depressive symptoms in patients with hypothyroidism despite standard thyroid hormone replacement therapy, with large effect sizes in a randomized controlled trial. (source: safarabadi-2026-the-effect-of-progressive-muscle-relaxation-technique-on.md)
Menopause in the Workplace
- Menopause is an increasingly recognized workplace health issue with significant implications for nursing practice, workforce retention, and employee wellbeing. Symptoms can impact performance, confidence, and attendance, but menopause remains under-discussed due to stigma and limited organizational support. Promoting awareness and normalizing conversations around menopause are essential to improving staff experience and sustaining a resilient workforce. (source: peate-2026-menopause-in-the-workplace.md)
- Among perimenopausal and postmenopausal women from the Dutch Lifelines cohort, 36.7% reported limitations in work functioning due to menopausal symptoms, and 45.5% of those did not discuss their symptoms at work. Perceived taboo was strongly associated with not discussing symptoms (OR 5.12), highlighting the need for open workplace culture and accessible support. (source: loef-2026-discussing-menopausal-symptoms-at-work-and-associations-with.md)
Military and Menopause
- A scoping review identified 18 articles on perimenopause and menopause in military contexts, mostly US-based (83%) and among veterans (67%). Key themes include menopausal knowledge, HRT use, experience of menopause, and available resources. Significant knowledge gaps remain, particularly regarding geographic differences and policy development. (source: segovia-2026-perimenopause-and-menopause-in-the-military-a-scoping.md)
Eye Health and Aging
- The Nrf2 signaling pathway plays a key role in protecting against oxidative stress and inflammation in age-related eye diseases (AREDs) like diabetic retinopathy, cataract, glaucoma, and age-related macular degeneration. Nrf2 activators, including noncoding RNAs and external substances, show promise in preclinical models, but issues like ocular delivery, long-term safety, and risks of chronic Nrf2 activation remain before clinical translation. (source: xinyu-2026-targeting-of-nuclear-factor-erythroid-2-related-factor-2.md)
- In the China Kadoorie Biobank, postmenopausal status showed one of the strongest positive associations with incident primary angle-closure glaucoma (PACG), alongside age and female sex, suggesting metabolic and vascular ageing may influence PACG beyond anatomical susceptibility. (source: shao-2026-risk-factors-of-primary-angle-closure-glaucoma-an-exposome-wide.md)
Breast Cancer
Breast Cancer and Tissue Stiffness
- High mammographic breast density is a strong independent risk factor for sporadic breast cancer. In a study of 108 postmenopausal women, dense breast tissue exhibited a distinct extracellular proteomic signature enriched for proteins associated with platelet activation. Several platelet-associated proteins were also elevated in ER+ breast cancers. Low-dose acetylsalicylic acid (ASA) did not modulate these proteins, suggesting that stiffness-induced platelet activation may occur via mechanotransduction rather than biochemical pathways. In a 3D in vitro model, increased matrix stiffness representative of dense breasts promoted a procoagulant platelet phenotype. These findings highlight platelet mechanobiology as a potential target for breast cancer prevention and therapy. (source: heenkenda-2026-tissue-stiffness-driven-platelet-activation-emerges-as-a-potentia.md)
Breast Cancer and Inflammation
- In a case-cohort study within the Melbourne Collaborative Cohort Study, the risk of postmenopausal ER+ breast cancer increased per doubling of blood concentrations of leptin (RR 1.13, 95% CI 1.03-1.25), adiponectin (RR 1.10, 95% CI 0.90-1.34), tumor necrosis factor-alpha (RR 1.27, 95% CI 0.96-1.68), and interleukin-10 (RR 1.14, 95% CI 1.01-1.29). The RR for a doubling of the leptin-to-adiponectin ratio was 1.07 (0.99-1.16). Other biomarkers (interferon-gamma, IL-6, IL-8, CRP) showed weaker associations. Systemic inflammation may be important in the risk of developing ER-positive breast cancer for postmenopausal females. (source: albers-2026-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-recepto.md)
Breast Cancer Treatment in Premenopausal Women
- Premenopausal women with HR+/HER2- early breast cancer represent a clinically distinct population with more aggressive tumor biology and unique survivorship concerns. Adjuvant endocrine therapy with CDK4/6 inhibitors in selected higher-risk patients remains the cornerstone of treatment. Major uncertainties persist regarding optimal use of ovarian function suppression, interpretation of genomic assays to inform chemotherapy decisions, selection of candidates for extended endocrine therapy, and management of adherence, toxicities, pregnancy-related issues, and survivorship. (source: licata-2026-navigating-uncertainties-and-evidence-gaps-in-adjuvant-therapy.md)
- The tumour microenvironment (TME) composition modulates tamoxifen benefit in postmenopausal ER+HER2- breast cancer. Low immune, intermediate endothelial, and low/intermediate fibroblast abundances are associated with improved benefit from tamoxifen, suggesting that both immune and stromal compartments influence endocrine treatment efficacy. (source: camargo-romera-2026-the-tumour-microenvironment-influences-long-term-tamoxifen-b.md)
Breast Cancer and Adipose Tissue
- In tumor-associated adipose tissue from breast cancer patients, perilipin 1 expression was increased in those with aggressive tumor characteristics, including advanced stage, premenopausal status, and obesity. In contrast, adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) levels were reduced in specific subgroups, particularly in obese and postmenopausal patients and in tumor-adjacent adipose tissue from invasive lobular carcinoma. These findings identify perilipin 1, ATGL, and HSL as potential candidate markers of tumor-adipocyte interactions in breast cancer. (source: pagnotta-2026-altered-lipolytic-protein-expression-in-tumor-associated-adipose-t.md)
Axillary Nodal Metastasis in Invasive Lobular Carcinoma
- Among patients with cT1N0, HR+/HER2- pure invasive lobular carcinoma (ILC) and normal axillary ultrasound, 17.7% had axillary nodal metastasis on surgical pathology, with only 2.3% having extensive nodal disease. Premenopausal status, high grade, and lymphovascular invasion (LVI) were associated with nodal positivity, but only LVI remained independently associated on multivariate analysis. These rates are comparable to the SOUND and INSEMA trials, supporting potential SLNB omission in selected ILC patients. (source: amburn-2026-axillary-nodal-upstaging-in-ct1n0-invasive-lobular-carcinoma.md)
Breast Cancer Biomarkers
- Serum 8-hydroxy-2-deoxyguanosine (8-OHdG) levels were significantly elevated in breast carcinoma (7.40±1.57 ng/mL) compared with benign breast disease (5.16±1.53 ng/mL; p<0.001) in a Bangladeshi cross-sectional study. At a cut-off of 6.0 ng/mL, 8-OHdG showed 71.4% sensitivity and 69.2% specificity for differentiating malignant from benign lesions. Increasing age, postmenopausal status, and family history were significantly associated with malignancy. 8-OHdG may serve as a practical non-invasive biomarker for diagnostic triage in resource-limited settings. (source: ferdoushi-2026-diagnostic-and-risk-stratification-value-of-serum-8-hydroxy-2-deo.md)
Breast Cancer Treatment Cost-Effectiveness
- From a Canadian public payer perspective, ribociclib plus an aromatase inhibitor (AI) yielded a probabilistic ICER of $45,097/QALY versus AI alone for adjuvant treatment of stage II and III HR+/HER2- early breast cancer, below the $50,000 willingness-to-pay threshold. Tamoxifen was dominated by AI alone. Results were most sensitive to iDFS hazard rates and ribociclib drug costs. (source: soliman-2026-cost-effectiveness-analysis-of-ribociclib-plus-an-aromatase-inhibit.md)
Breast Cancer Mortality and Cholesterol
- In the Multiethnic Cohort Study, pre-diagnostic plasma levels of 27-hydroxycholesterol (27HC), estrone, testosterone, and SHBG were measured on average 6.7 years before breast cancer diagnosis in 1,009 postmenopausal females not using menopausal hormone therapy. Associations with mortality were examined prospectively, with hazard ratios estimated using multivariable models. (source: sangaramoorthy-2026-circulating-27-hydroxycholesterol-sex-steroid-hormones-and-r.md)
Menopause Industry and Economics
- The 'silver economy' of women's health: entrepreneurship and service models in China's menopause health sector. (source: zhang-2026-the-silver-economy-of-women-s-health-entrepreneurship-and.md)
Menopause and Financial Decision-Making
- The Behavioral Finance-Menopausal Cognition (BF-MC) Model, based on the MARiE WP2a study of over 6,300 women across 13 countries, proposes that menopause-related neurocognitive, emotional, and sociostructural changes may influence financial decision-making. The model identifies four domains: neurocognitive regulation, affective-behavioral regulation, sociostructural mediation, and economic adaptation/resilience. It reframes midlife women's financial behavior as a dynamic biopsychosocial process, though pathways require validation with longitudinal financial data. (source: delanerolle-2026-integrating-menopausal-neurocognitive-and-psychosocial-dynamics.md)
Obesity, Incretin-Based Therapies, and Cardiovascular Disease
- Obesity in women is a growing public health challenge driven by complex interactions among biological, hormonal, and psychosocial factors across the life course. Hormonal fluctuations from menarche to menopause influence fat distribution, energy balance, and metabolic risk. Women-specific conditions like pregnancy-related weight retention, hypertensive disorders of pregnancy, and polyendocrine metabolic ovarian syndrome further amplify long-term cardiometabolic risk. Women with obesity have an increased risk of heart failure with preserved ejection fraction and ischemia with non-obstructive coronary arteries. Emerging incretin-based therapies for obesity offer substantial weight loss and cardiovascular benefits, but sex-specific differences in efficacy, tolerability, and long-term outcomes remain insufficiently researched. (source: salih-2026-obesity-incretin-based-therapies-and-cardiovascular-disease-in-women.md)
BRCA1/2 Previvors
- Previvors carrying a germline pathogenic or likely pathogenic variant in BRCA1 or BRCA2 require comprehensive care that includes counseling on risk-reduction options, the safety and benefits of estrogen-only HRT, lifestyle modification strategies, and targeted nutrition guidance. (source: gopal-2026-bridging-the-brca1-2-variant-previvor-gap-in-health.md)
Dermatomyositis and Cervical Cancer
- A 61-year-old postmenopausal woman presenting with dermatomyositis (DM) was found to have an underlying non-keratinizing squamous cell carcinoma of the cervix (Stage IIB). The patient showed significant clinical recovery in both muscle strength and dysphagia following concurrent chemoradiotherapy, highlighting the importance of evaluating patients with new-onset DM for occult malignancy. (source: chapagain-2026-dermatomyositis-as-a-paraneoplastic-syndrome-secondary-to-carcino.md)
Bacterial Small RNAs and Osteoimmune Diseases
- Bacterial small RNAs (sRNAs) and vesicle-associated RNA signals play roles in inflammatory and osteoimmune diseases, including postmenopausal osteoporosis. The most robust mechanistic example is Porphyromonas gingivalis vesicle-associated sRNA45033, which targets the 3' untranslated region of CBX5 and regulates apoptosis in periodontal ligament cells. Future research integrating small RNA sequencing, metatranscriptomics, and extracellular vesicle profiling is required to establish causal roles and biomarker potential. (source: montes-garcia-2026-bacterial-small-rnas-and-extracellular-vesicles-in-inflammato.md)
Cardiovascular-Kidney-Metabolic Syndrome in Women
- The American Heart Association introduced Cardiovascular-Kidney-Metabolic (CKM) syndrome, a five-stage framework (Stages 0-4) that categorizes individuals based on disease progression and risk. This framework is particularly significant for women, as sex-specific risk enhancers including premature menopause and adverse pregnancy outcomes influence CKM stage classification and long-term outcomes. The PREVENT risk equations are sex-specific, race-neutral models designed to estimate absolute 10- and 30-year risk for total cardiovascular disease. (source: kurian-2026-cardiovascular-kidney-metabolic-syndrome-in-women-bridging-nephrolog.md)
Women's Health in Kidney Disease
- Chronic kidney disease (CKD) affects women differently than men, with women more commonly having early-stage CKD but progressing more slowly to kidney failure. Pregnancy-related exposures, particularly adverse pregnancy outcomes such as preeclampsia, are associated with substantially increased long-term risk of CKD and ESKD. Menopause may represent a key inflection point for CKD progression and bone health. Additional disparities affect transplant access, and cancer survivorship introduces underrecognized renal risks. (source: sarav-2026-reframing-women-s-health-in-kidney-disease-sex-differences.md)
Nocturia in Postmenopausal Women
- Nocturia, defined as waking during the night to urinate one or more times, is a prevalent condition among postmenopausal women, significantly affecting quality of life. The postmenopausal period is associated with hormonal, anatomical, functional, and psychosocial changes that predispose women to nocturia. Understanding its etiology is essential for targeted management. (source: simon-2026-nocturia-in-postmenopausal-women.md)
Vaginal and Cervical HPV Infection
- In a retrospective cross-sectional study from Shanxi, China, the most common HPV genotypes in vaginal intraepithelial neoplasia (VaIN) and vaginal cancer were HPV16, 52, 58, 53, and 18. The HPV positive rate was 95.5% in VaIN2/3, 86.0% in vaginal squamous cell carcinoma, and 43.8% in vaginal adenocarcinoma. HPV18 had the highest positive rate in vaginal adenocarcinoma. Active HPV vaccination may help reduce the burden of these lesions. (source: guo-2026-human-papillomavirus-infection-in-patients-with-vain-and.md)
Endometrial Cancer and Estradiol Signaling
- In postmenopausal women with low estrogen receptor α (ERα) endometrial cancer, serum estradiol levels were elevated, and 67.7% showed high tumor expression of GPER. Estradiol promoted tumor progression in ERα-low endometrial cancer via the GPER/SphK1/ERK1/2 pathway, activating Cyclin D1, Cyclin E1, and MMP-9. In a mouse xenograft model, E2 stimulated tumor growth, an effect mitigated by inhibitors of GPER, SphK1, and ERK, revealing potential therapeutic targets for this high-risk subgroup. (source: wang-2026-estradiol-promotes-tumor-progression-in-er-low-endometrial-cancer.md)
Turner Syndrome
- Turner syndrome is a sex chromosome abnormality in female individuals characterized by the complete or partial loss of one X chromosome, occurring in approximately 1 in 2000 female individuals. It is associated with a wide range of clinical characteristics including short stature, hypergonadotropic hypogonadism, ovarian dysgenesis, delayed puberty, infertility, and congenital heart disease. (source: gravholt-2026-new-genomic-understanding-and-challenges-in-clinical-care.md)
Complex Menopause Care
- A rapid review of complex menopause care in tertiary settings identified key themes including the use of interdisciplinary care teams, unique needs for unique populations (e.g., premature ovarian insufficiency, HIV, gynecologic or breast cancer), and psychosocial concerns in these populations. Gaps in care delivery persist, and tertiary clinics should incorporate a wider array of specialists, including nonphysician practitioners, to allow for holistic care. (source: hira-2026-mapping-menopause-a-rapid-review-exploring-complex-menopause.md)
Healthy Aging and Menopause
- Menopause is an important biological transition with up to 72 symptoms that shapes aging trajectories across organs and encompasses about 40% of the female lifespan. Optimized menopause care necessitates a precision medicine approach that considers menopause symptoms, genetics, and previous hormone exposures. (source: gravelsins-2026-reframing-menopause-and-menopause-hormone-therapy-as-opportuniti.md)
Hysteroscopic Procedures
- Office vaginoscopic hysteroscopy with an 18.5 Fr hysteroscope and blue laser was used successfully for no-anesthesia removal of an IUD-myoma complex in a 56-year-old postmenopausal woman with severe cervical atrophy. The 36-minute procedure was well tolerated (VAS pain 3/10), with no complications and a normal uterine cavity on 1-week follow-up ultrasound. (source: li-2026-office-hysteroscopic-removal-of-an-iud-myoma-composite-using.md)
Uterine Myomas and Hysterectomy
- TVH was associated with significantly shorter operative time, lower intraoperative blood loss, and reduced hospital stay compared to TAH for uterine myomas in postmenopausal women, with similar age, uterine weight, BMI, and parity. However, TAH patients had more medical/surgical histories, postoperative complications (11.44% vs 4.29%), and adhesions (32.86% vs 20%). Uterine hemisection, tactical myomectomy, or morcellation were used in 78.57% of TVH cases. (source: nicodin-2026-the-role-of-total-vaginal-hysterectomy-versus-total.md)
Androgen Insensitivity Syndrome
- A 29-year-old phenotypic female with complete androgen insensitivity syndrome (AIS) presented with primary amenorrhea, normal breast development, sparse pubic hair, and absent Müllerian structures. After laparoscopic bilateral orchiectomy (prophylactic gonadectomy), she received postoperative hormone replacement therapy with resolution of abdominal pain and improved psychological well-being. Diagnosis required considering 46, XY disorder of sex development (46,XY DSD), and multidisciplinary care is essential. (source: zhang-2026-androgen-insensitivity-syndrome-a-case-report.md)
Private · Mined nightly from your Obsidian vaults · ← All Wikis